Over a median follow-up of 2.4 years, dapagliflozin led to a highly significant 31% risk reduction of all-cause mortality with a significant reduction in patients both with and without diabetes; moreover, the results were consistent across all other pre-specified subgroups.
← all excerpts
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial.
1
—
—